Journal Mobile Options
Table of Contents
Vol. 31, No. 4, 2008
Issue release date: April 2008
Onkologie 2008;31:174–178
(DOI:10.1159/000116736)
Original Article · Originalarbeit

EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients

Wang Z. · Wu Y.L. · Zhang G.C. · Zhou Q. · Xu C.R. · Guo A.L.
Guangdong Provincial People’s Hospital, Cancer Center, Guangdong Provincial Lung Cancer Research Institute, Guangzhou, China

Abstract

Background: For gefitinib treatment for non-small cell lung cancer (NSCLC), KRAS mutations reportedly behave as a resistance marker, and the epidermal growth factor receptor (EGFR) as a responsive marker. It is known that Asians and Caucasians have different responses to gefitinib. We investigated the KRAS and EGFR mutation status in a group of Chinese patients with advanced NSCLC who were treated with gefitinib after a failed chemotherapy. Material and Methods: Genomic DNA extracted from tumor specimens of 24 patients with advanced NSCLC, who failed at least 1 prior platinum-based chemotherapy regimen before gefitinib treatment, was subjected to nested polymerase chain reaction (PCR) to amplify codons 12, 13, 59, and 61 of the KRAS gene and exons 18–21 of the EGFR gene for direct sequencing. Results: For the 24 patients, no KRAS gene mutation was found. 15 patients (62.5%, 15/24) harbored EGFR mutations which included deletion mutations in exon 19 and missense mutations in exon 21. Conclusion: KRAS mutation may occur at a very low frequency in Chinese NSCLC patients regardless of pathology, smoking status, or gender. Unlike EGFR, the low incidence of KRAS mutations may undermine its role in predicting the clinical response to EGFR tyrosine kinase inhibitors.

 goto top of outline Author Contacts

Dr. Yi Long Wu, Guangdong Provincial People’s Hospital, Cancer Center, Guangdong Provincial Lung Cancer Research Institute, 106 Zhongshan 2nd Road, Guangzhou, Guangdong, 510080, China, Tel. +8620 838-21484, Fax -27712 E-mail gzyilong@hotmail.com


 goto top of outline Article Information

Published online: March 20, 2008
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 0, Number of References : 0


 goto top of outline Publication Details

Onkologie (International Journal for Cancer Research and Treatment)

Vol. 31, No. 4, Year 2008 (Cover Date: April 2008)

Journal Editor: Schmoll H.-J. (Halle)
ISSN: 0378–584X (Print), eISSN: 1423–0240 (Online)

For additional information: http://www.karger.com/ONK


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.